Publication:
Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.

cris.virtualsource.author-orcid3ffc609d-4653-413a-a80f-2bf6c2b71f47
dc.contributor.authorAhmed, Sairah
dc.contributor.authorKanakry, Jennifer A
dc.contributor.authorAhn, Kwang W
dc.contributor.authorLitovich, Carlos
dc.contributor.authorAbdel-Azim, Hisham
dc.contributor.authorAljurf, Mahmoud
dc.contributor.authorBacher, Vera Ulrike
dc.contributor.authorBejanyan, Nelli
dc.contributor.authorCohen, Jonathon B
dc.contributor.authorFarooq, Umar
dc.contributor.authorFuchs, Ephraim J
dc.contributor.authorBolaños-Meade, Javier
dc.contributor.authorGhosh, Nilanjan
dc.contributor.authorHerrera, Alex F
dc.contributor.authorHossain, Nasheed M
dc.contributor.authorInwards, David
dc.contributor.authorKanate, Abraham S
dc.contributor.authorMartino, Rodrigo
dc.contributor.authorMunshi, Pashna N
dc.contributor.authorMurthy, Hemant
dc.contributor.authorMussetti, Alberto
dc.contributor.authorNieto, Yago
dc.contributor.authorPerales, Miguel-Angel
dc.contributor.authorRomee, Rizwan
dc.contributor.authorSavani, Bipin N
dc.contributor.authorSeo, Sachiko
dc.contributor.authorWirk, Baldeep
dc.contributor.authorYared, Jean A
dc.contributor.authorSureda, Ana
dc.contributor.authorFenske, Timothy S
dc.contributor.authorHamadani, Mehdi
dc.date.accessioned2024-10-28T17:17:24Z
dc.date.available2024-10-28T17:17:24Z
dc.date.issued2019-09
dc.description.abstractClassic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning (RIC) HCT platforms in cHL: T cell-replete related donor haploidentical (haplo) HCT with a post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin inhibitor (CNI)-based approach. The study included 596 adult patients who underwent a first RIC allo-HCT for cHL between 2008 and 2016 using either a haplo-PTCy (n = 139) or MSD/CNI-based (n = 457) approach. Overall survival (OS) was the primary endpoint. Secondary endpoints included acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD), nonrelapse mortality (NRM), relapse/progression, and progression-free survival (PFS). On multivariate analysis, there was no significant difference between haplo/PTCy and MDS/CNI-based approaches in terms of OS (hazard ratio [HR], 1.07; 95% confidence interval [CI], .79 to 1.45; P = .66) or PFS (HR, .86; 95% CI, .68 to 1.10; P = .22). Haplo/PTCy was associated with a significantly higher risk of grades II to IV aGVHD (odds ratio [OR], 1.73, 95% CI, 1.16 to 2.59; P = .007), but the risk of grades III to IV aGVHD was not significantly different between the 2 cohorts (OR, .61; 95% CI, .29 to 1.27; P = .19). The haplo/PTCy platform provided a significant reduction in cGVHD risk (HR, .45; 95% CI, .32 to .64; P < .001), and a significant reduction in relapse risk (HR, .74; 95% CI, .56 to .97; P = .03). There was a statistically nonsignificant trend toward higher NRM with a haplo/PTCy approach (HR, 1.65; 95% CI, .99 to 2.77; P = .06). Haplo/PTCy-based approaches are associated with lower incidences of cGVHD and relapse, with PFS and OS outcomes comparable with MSD/CNI-based approaches. There was a leaning toward higher NRM with a haplo/PTCy-based platform. These data show that haplo/PTCy allo-HCT in cHL results in survival comparable with MSD/CNI-based allo-HCT.
dc.description.numberOfPages10
dc.description.sponsorshipUniversitätsklinik für Hämatologie und Hämatologisches Zentrallabor
dc.identifier.doi10.7892/boris.133199
dc.identifier.pmid31132455
dc.identifier.publisherDOI10.1016/j.bbmt.2019.05.025
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/182095
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofBiology of blood and marrow transplantation
dc.relation.issn1083-8791
dc.relation.organizationDCD5A442C055E17DE0405C82790C4DE2
dc.subjectAllogeneic transplantation Alternative donor Haploidentical transplantation Hodgkin lymphoma
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleLower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.endPage1868
oaire.citation.issue9
oaire.citation.startPage1859
oaire.citation.volume25
oairecerif.author.affiliationUniversitätsklinik für Hämatologie und Hämatologisches Zentrallabor
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2019-11-13 15:00:43
unibe.description.ispublishedpub
unibe.eprints.legacyId133199
unibe.journal.abbrevTitleBIOL BLOOD MARROW TR
unibe.refereedTRUE
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
Lower Graft.pdf
Size:
680.67 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
publisher
Content:
published

Collections